Editorials

Immunosuppressive drugs after lung transplantation

BMJ 1998; 316 doi: https://doi.org/10.1136/bmj.316.7133.719 (Published 07 March 1998) Cite this as: BMJ 1998;316:719

New agents may improve long term survival

  1. Norman Briffa, Research fellow,
  2. Randall E Morris, Director
  1. Laboratory for Transplantation Immunology, Department of Cardiothoracic Surgery, Stanford University School of Medicine, Stanford, CA 94305-5247, USA

    Survival figures after lung transplantation for the period up to 1996 were reported at a recent annual meeting of the International Society of Heart and Lung Transplantation in London. Although quality of life for patients is greatly improved for some years after transplantation, five year survival after heart-lung, single lung, or double lung transplantation is still less than 50%.1 Mortality in the first 30 days has improved because of advances in surgical technique and in methods of lung preservation,1 but after 30 days the survival curves in 1988-91 and in 1992-5 are parallel.

    The main cause of death between 30 days and a year after transplantation is infection. After a year the main cause is bronchiolitis obliterans syndrome. This fibroproliferative disorder affects the small airways of at least half of patients who survive for three months after transplantation.2 Its pathogenesis is unclear but it represents a fibrotic repair process occurring after chronic airway injury, and retrospective series have shown that acute lung rejection is an important risk factor for its development.2 New treatments for bronchiolitis obliterans syndrome and steroid resistant rejection have included trials of inhaled cyclosporin, total lymphoid irradiation, and methotrexate.35 However, since infection is still an important cause of death after lung transplantation,6 further gains in survival will be difficult to achieve with current immunosuppressive regimens: cyclosporin, azathioprine, steroids, and cytolytic drugs. More effective immunosuppressive drugs are needed, and clinical trials evaluating new immnuosuppressive agents in lung transplantation are planned. Currently, encouraging results have been reported with these drugs after renal transplantation.

    Better absorption of a new formulation of cyclosporin—cyclosporin microemulsion formulation (Neoral, Novartis)—increases overall exposure of patient and graft to cyclosporin without an increase in toxicity. The improved pharmacokinetic profile has been shown in healthy human volunteers and stable renal and lung transplant patients, including patients with cystic fibrosis.7

    Tacrolimus is the United States approved name for FK506 (Prograf, Fujisawa). Gjertson et al examined data from the United Network for Organ Sharing kidney transplant registry on 38 057 patients who had been discharged after their first cadaveric kidney transplant.8 They compared kidney half life in different treatment groups and found it was 13.8 years for patients taking tacrolimus, 8.8 years for patients taking cyclosporin, and 7.7 years for patients taking other drugs. The authors stated that FK506 seemed to be the first drug significantly to improve long term survival of kidney grafts.

    In the only properly controlled study comparing cyclosporin and tacrolimus treatments in lung transplantation there was a trend towards improved survival at two years in the tacrolimus group and a reduction in rejection episodes (0.85/100 patient days for tacrolimus and 1.09/100 patient days for cyclosporin; p=0.07).9 Notably, however, fewer patients in the tacrolimus group developed obliterative bronchiolitis compared with the cyclosporin group (21.7% v 35.8%, P=0.025). Tacrolimus may be effective in treating persistent rejection and in slowing down deterioration in airflow that occurs with bronchiolitis obliterans syndrome.10

    Mycophenolate mofetil (Cellsept, Hoffmann LaRoche) is a morpholinoethyl ester of mycophenolic acid and has been more extensively studied in controlled, open, and blinded clinical trials than any other new immunosuppressant. In all studies mycophenolate has been substituted for azathioprine in triple drug regimens. In a pooled efficacy analysis of three large, randomised, double blind, clinical trials of renal transplantation, the mycophenolate groups showed better survival of grafts and fewer rejection episodes (19.8% and 16.5% for mycophenolate 2 and 3 g v 40.8% for azathioprine, p<0.0001).11 There was no difference in infection rates between patients in the azathioprine group and the mycophenolate group.11

    Three lung transplant centres recently reported their initial experience of mycophenolate mofetil in lung transplantation.10 None of the studies was properly controlled, and each contained relatively small numbers of patients. All the studies reported significantly fewer episodes of acute rejection, proved by biopsy, without a significant increase in infection. In one paper the authors detected a significantly smaller drop in forced expiratory volume in one second in the mycophenolate group.10

    Sirolimus (US approved name for rapamycin—Rapimmune, Wyeth, and RAD rapamycin derivative, Novartis) is structurally similar to tacrolimus but has a different mode of action.12 Recently published phase II trials in renal transplant patients suggest that the drug can decrease acute rejection rates from 40% to less than 10% among patients taking full dose cyclosporin.13 This improvement is achieved with a small, non-significant increase in infectious complications. The authors suggest that the drug may mitigate the need for long term steroid treatment.

    Randomised controlled trials comparing mycophenolate mofetil and rapamycin or rapamycin derivative with azathioprine are now in the planning stages. These new drugs will soon form the basis of new immunosuppressive regimens for use in lung transplantation that are expected to have an impact on long term survival.

    Acknowledgments

    NB is supported in part by the Sandoz study grant of the European Society of Transplantation.

    References

    1. 1.
    2. 2.
    3. 3.
    4. 4.
    5. 5.
    6. 6.
    7. 7.
    8. 8.
    9. 9.
    10. 10.
    11. 11.
    12. 12.
    13. 13.
    View Abstract

    Sign in

    Log in through your institution

    Free trial

    Register for a free trial to thebmj.com to receive unlimited access to all content on thebmj.com for 14 days.
    Sign up for a free trial

    Subscribe